Nanjing, China · Founded 2021 · Privately Held (backing)
Developer of clinical-stage biopharmaceuticals designed for innovative immunotherapies targeting respiratory diseases, including cancer. JSIAMA Biopharmaceuticals is based in Nanjing, China and was founded in 2021. Its last reported valuation was $66.2 million in Mar 2025. It has raised $6.9 million.
Last reported valuation
$66.2M
Oct 2026
Priced at
—
Total raised
$6.9M
Last round
—
Cap table — not yet on record
JSIAMA Biopharmaceuticals's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of JSIAMA Biopharmaceuticals with a free account
·Watch JSIAMA Biopharmaceuticals: the Monday email on marks, rounds and moves
